Business
Zealand Pharma Announces Financial Results for the First Three Months of 2025
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth. Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related indica
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Company announcement – No. 11 / 2025","length":36,"tagName":"p"},{"type":"text","content":"Zealand Pharma Announces Financial Results for the First Three Months of 2025","length":77,"tagName":"p"},{"type":"text","content":"Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth.","length":184,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related indications, aiming to establish the leading amylin-based franchise.","length":262,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrolled the last participant in the large, global Phase 2 ZUPREME-1 trial with petrelintide in people with overweight or obesity, three months after trial initiation.","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed Utpal Singh as Chief Scientific Officer in April 2025 to lead the next wave of differentiated and innovative medicines, building on Zealand Pharma’s strong peptide heritage and its ambition to become a generational biotech company.","length":241,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":670,"olType":false},{"type":"text","content":"Copenhagen, Denmark, May 8, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the interim report for the three months ended March 31, 2025, and provided a corporate update.","length":303,"tagName":"p"},{"type":"text","content":"Embarking on a new chapter with transformative partnership for petrelin...